Anixa Biosciences (ANIX) EBITDA (2010 - 2026)

Anixa Biosciences (ANIX) has reported EBITDA for 17 consecutive years, with -$2.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 11.85% year-over-year to -$2.6 million; the trailing twelve-month figure through Apr 2026 stood at -$11.0 million (up 16.6% YoY), and the FY2025 full-year result was -$11.7 million, up 15.4% from the prior year.
• EBITDA advanced to -$2.6 million in Q2 2026 per ANIX's latest filing, from -$2.9 million in the prior quarter.
• Across five years, EBITDA topped out at -$2.4 million in Q3 2025 and bottomed at -$3.9 million in Q1 2022.
• Historically, EBITDA has averaged -$3.1 million across 5 years, with a median of -$3.1 million in 2023.
• The widest YoY moves for EBITDA: up 36.26% in 2022, down 73.76% in 2022.
• Over 5 years, EBITDA stood at -$3.6 million in 2022, then climbed by 15.46% to -$3.1 million in 2023, then decreased by 3.67% to -$3.2 million in 2024, then increased by 9.07% to -$2.9 million in 2025, then gained by 7.96% to -$2.6 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$2.6 million, -$2.9 million, and -$2.4 million for Q2 2026, Q4 2025, and Q3 2025 respectively.